NCM
PVLA

Nantahala Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Nantahala Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250,062
Closed -$15.7M – 172
2025
Q3 		$15.7M Hold
250,062
– – 0.54% 44
2025
Q2 		$5.64M Hold
250,062
– – 0.22% 88
2025
Q1 		$7M Hold
250,062
– – 0.28% 56
2024
Q4 		$3M Buy
+250,062
New +$3.93M 0.13% 100
2019
Q3 		– Sell
-18,470
Closed -$6.95M – 98
2019
Q2 		$6.95M Buy
18,470
+1,494
+9% +$446K 0.21% 65
2019
Q1 		$4.55M Hold
16,976
– – 0.14% 74
2018
Q4 		$3.61M Buy
16,976
+9,028
+114% +$2.8M 0.11% 84
2018
Q3 		$3.56M Buy
+7,948
New +$3.45M 0.1% 82

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Nantahala Capital Management's PVLA Position: Q4 2025 in Review

Nantahala Capital Management sold out of Palvella Therapeutics (PVLA) in Q4 2025, closing a stake of 250,062 shares — an estimated $15.7M sold.

Nantahala Capital Management first reported a position in PVLA in Q3 2018 and held it in 8 quarters. The position peaked at $15.7M in Q3 2025. 140 funds tracked by Wall St. Rank hold PVLA as of Q4 2025.

  • Nantahala Capital Management reported no remaining Palvella Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 250,062 Palvella Therapeutics shares in Q4 2025, an estimated $15.7M.
  • Nantahala Capital Management first reported a position in Palvella Therapeutics in Q3 2018 and held it in 8 quarters.
  • Nantahala Capital Management's Palvella Therapeutics position peaked at $15.7M in Q3 2025.
  • 140 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.